Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Volume 36, Issue 2, February 2011, Pages 91-170
 
MONOGRAPHS
 
  
 Crizotinib.
ALK/Met inhibitor, Oncolytic.
Nwizu, T., Kanteti, R., Kawada, I., Rolle, C., Vokes, E.E., Salgia, R.
Drugs Fut 2011, 36(2): 91
Full Text: HTMLPDF 
 
  
  
 Vorapaxar.
PAR1 receptor antagonist, Antiplatelet therapy.
Goto, S., Serebruany, V.
Drugs Fut 2011, 36(2): 101
Full Text: HTMLPDF 
 
  
 
REVIEW ARTICLES
 
  
 Perspectives in the treatment of pruritus: Focus on new strategies.
Tey, H.L., Yosipovitch, G.
Drugs Fut 2011, 36(2): 115
Summary | Full Text: HTMLPDF 
 
  
  
 The role of neurotrophins and mimetics in the treatment of ocular diseases.
Bai, Y., Ge, J., Saragovi, H.U., Zhuo, Y.
Drugs Fut 2011, 36(2): 123
Summary | Full Text: HTMLPDF 
 
  
 
FILLING THE GAPS IN DRUG THERAPY
 
  
 Targeting early events in cystic fibrosis disease pathogenesis.
Hoover, W., Clancy, J.P.
Drugs Fut 2011, 36(2): 133
Summary | Full Text: HTMLPDF 
 
  
 
TARGETS TO WATCH
 
  
 Acidic mammalian chitinase (AMCase): a new target for ocular diseases.
Musumeci, M., Bucolo, C., Drago, F., Musumeci, S.
Drugs Fut 2011, 36(2): 141
Summary | Full Text: HTMLPDF 
 
  
 
MEETING REPORTS
 
  
 Emerging treatment options for type 2 diabetes: Highlights from the 46th Annual Meeting of the European Association for the Study of Diabetes (September 20-24, 2010, Stockholm, Sweden).
Bandyopadhyay, P.
Drugs Fut 2011, 36(2): 149
Summary | Full Text: HTMLPDF 
 
  
  
 Joint 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and 15th Conference of Rehabilitation in Multiple Sclerosis (RIMS): An update on clinical findings to improve outcomes in multiple sclerosis.
Vasiliou, S.
Drugs Fut 2011, 36(2): 159
Summary | Full Text: HTMLPDF 
 
  
 
  



© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy